ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lun…

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...
Morning Overview on MSN

Scientists find a way to turbocharge cancer-fighting immunity

Cancer immunotherapy has already transformed treatment for some patients, yet too often the body’s defenders stall out before ...
Seeking Alpha

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access ...
Medscape

Pregnancy and Breastfeeding May Reprogram Breast Immunity

Pregnancy and breastfeeding leave behind long-lived CD8+ T lymphocytes that provide lasting immune protection in breast tissue, according to new research, a discovery that could reshape understanding ...
EurekAlert!

Predictive biomarkers for immunotherapy in nasopharyngeal carcinoma: From tumor microenvironment to macroenvironment

The integration of PD-1 inhibitors into standard chemotherapy and radiotherapy regimens has revolutionized nasopharyngeal carcinoma treatment, yet only a minority of patients achieve durable responses ...